Parallax Volatility Advisers
MRNA icon

Parallax Volatility Advisers’s Moderna MRNA Stock Holding History

Parallax Volatility Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$590K – 1719
2025
Q4 		$590K Sell
20,000
-100,000
-83% -$2.72M ﹤0.01% 1201
2025
Q3 		$3.1M Hold
120,000
– – ﹤0.01% 801
2025
Q2 		$3.31M Sell
120,000
-33,000
-22% -$869K 0.01% 734
2025
Q1 		$4.34M Buy
153,000
+74,600
+95% +$2.65M 0.01% 655
2024
Q4 		$3.26M Sell
78,400
-8,100
-9% -$387K 0.01% 986
2024
Q3 		$5.78M Sell
86,500
-126,100
-59% -$11.6M 0.01% 735
2024
Q2 		$25.2M Sell
212,600
-27,300
-11% -$3.45M 0.05% 249
2024
Q1 		$25.6M Buy
239,900
+112,700
+89% +$11.4M 0.06% 256
2023
Q4 		$12.7M Sell
127,200
-22,300
-15% -$1.88M 0.03% 522
2023
Q3 		$15.4M Sell
149,500
-26,300
-15% -$2.93M 0.03% 401
2023
Q2 		$21.4M Sell
175,800
-222,500
-56% -$29.7M 0.05% 324
2023
Q1 		$61.2M Sell
398,300
-1,261,700
-76% -$208M 0.13% 155
2022
Q4 		$298M Buy
1,660,000
+292,100
+21% +$47.8M 0.46% 30
2022
Q3 		$162M Buy
1,367,900
+332,600
+32% +$50.5M 0.25% 59
2022
Q2 		$148M Buy
1,035,300
+634,000
+158% +$90.6M 0.14% 100
2022
Q1 		$69.1M Sell
401,300
-811,400
-67% -$137M 0.04% 206
2021
Q4 		$308M Buy
1,212,700
+155,600
+15% +$45.5M 0.28% 43
2021
Q3 		$407M Buy
1,057,100
+786,800
+291% +$290M 0.31% 35
2021
Q2 		$63.5M Buy
270,300
+83,300
+45% +$14.9M 0.06% 257
2021
Q1 		$24.5M Sell
187,000
-85,000
-31% -$12.3M 0.02% 594
2020
Q4 		$28.4M Buy
272,000
+232,000
+580% +$23.5M 0.02% 635
2020
Q3 		$2.83M Buy
+40,000
New +$2.79M ﹤0.01% 1562
2020
Q2 		– Sell
-80,000
Closed -$2.4M – 2810
2020
Q1 		$2.4M Buy
+80,000
New +$1.84M ﹤0.01% 1154

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Parallax Volatility Advisers's MRNA Position: Q2 2026 in Review

Parallax Volatility Advisers reduced its Moderna (MRNA) stake by 18% in Q2 2026, selling an estimated $436K and leaving 39,458 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #735.

Parallax Volatility Advisers first reported a position in MRNA in Q1 2020 and has held it in 23 quarters since. The position peaked at $27.4M in Q4 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Parallax Volatility Advisers held 39,458 shares of Moderna worth $2.76M as of Q2 2026.
  • Parallax Volatility Advisers sold 8,433 Moderna shares in Q2 2026, an estimated $436K.
  • Moderna made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #735 holding.
  • Parallax Volatility Advisers first reported a position in Moderna in Q1 2020 and has held it in 23 quarters since.
  • Parallax Volatility Advisers's Moderna position peaked at $27.4M in Q4 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.